Home WebMail Saturday, November 2, 2024, 02:23 PM | Calgary | 4.5°C | Regions Advertise Login | Our platform is in maintenance mode. Some URLs may not be available. |
Posted: 2017-03-31T17:58:47Z | Updated: 2017-03-31T17:58:47Z

Israeli chemist Raphael Mechoulam spent decades unlocking the mysteries of marijuana in a lab, but his fascination with one of the worlds most popular drugs never led to personal experimentation, he said in a recent interview.

I have never used it, Mechoulam told Culture Magazine earlier this month. First of all, I am still interested, but as I did research and we had [an] official supply of cannabis, obviously if we had used it for non-scientific reasons, if people had come to know about it that would have stopped our work. Basically, neither I nor my students were interested.

Ethical self-restraint is just a small part of Mechoulams story. His research into the pharmacology of cannabinoids began in the early 1960s with a batch of hashish that police passed to him out of an evidence locker.

Over the next few years, his group would become the first to isolate and synthesize cannabidiol, or CBD, now revered for its potential medical applications, as well as tetrahydrocannabinol, or THC, the psychoactive compound in marijuana that makes users feel high.

Mechoulams work also opened the door for more recent developments in the field of marijuana medicine. Studies have shown that cannabinoids have promise in the treatment of ailments including cancer , epilepsy , chronic pain , anxiety and even some psychotic symptoms .

There appears to be a bright future for the research Mechoulam pioneered, especially in Israel, where marijuana has been legal for medical purposes since the 1990s.

Although a total of 28 U.S. states have legalized marijuana for medical purposes and eight states and Washington, D.C., have approved it for recreational use it remains illegal in the country at the federal level, which has complicated U.S. scientific research efforts. Israel, on the other hand, has embraced a role as a leader in marijuana research .

Your Support Has Never Been More Critical

Other news outlets have retreated behind paywalls. At HuffPost, we believe journalism should be free for everyone.

Would you help us provide essential information to our readers during this critical time? We can't do it without you.

You've supported HuffPost before, and we'll be honest we could use your help again . We view our mission to provide free, fair news as critically important in this crucial moment, and we can't do it without you.

Whether you give once or many more times, we appreciate your contribution to keeping our journalism free for all.

You've supported HuffPost before, and we'll be honest we could use your help again . We view our mission to provide free, fair news as critically important in this crucial moment, and we can't do it without you.

Whether you give just one more time or sign up again to contribute regularly, we appreciate you playing a part in keeping our journalism free for all.

Support HuffPost

In 2012, Israeli researchers were among the first to successfully breed a marijuana plant that contained no THC but high levels of CBD. Earlier this year, the nation began considering steps to decriminalize marijuana use and allow export of medical marijuana products .

Mechoulam is officially retired now, but he believes theres still plenty of work to do to fully uncover the therapeutic potential of the compounds he discovered more than 50 years ago.

There have been very, very few clinical studies, he told Culture. Although thousands of people use cannabis to fight cancer, there hasnt been any clinical study, or a well-done, modern clinical study on cancer published. Thats a shame because if people use it, the data should be there. We should have modern clinical data.